Research Article

You have full text access to this OnlineOpen article

A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications

  1. Andrew J. Holman*,
  2. Robin R. Myers

Article first published online: 28 JUL 2005

DOI: 10.1002/art.21191

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 52, Issue 8, pages 2495–2505, August 2005

Additional Information

How to Cite

Holman, A. J. and Myers, R. R. (2005), A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis & Rheumatism, 52: 2495–2505. doi: 10.1002/art.21191

Author Information

  1. Pacific Rheumatology Associates, Renton, Washington

*Pacific Rheumatology Associates, 4300 Talbot Road South, Suite 101, Renton, Washington 98055

Publication History

  1. Issue published online: 28 JUL 2005
  2. Article first published online: 28 JUL 2005
  3. Manuscript Accepted: 19 APR 2005
  4. Manuscript Received: 20 DEC 2004

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (113K)

REFERENCES

  • 1
    Martinez- Lavin M, Hermosillo AG, Rosas M, Soto ME. Circadian studies of autonomic nervous balance in patients with fibromyalgia: a heart rate variability analysis. Arthritis Rheum 1998; 41: 1966–71.
    Direct Link:
  • 2
    Petzke F, Clauw DJ. Sympathetic nervous system function in fibromyalgia. Curr Rheumatol Rep 2000; 2: 116–23.
  • 3
    Raj SR, Brouillard D, Simpson CS, Hopman WM, Abdollah H. Dysautonomia among patients with fibromyalgia: a noninvasive assessment. J Rheumatol 2000; 27: 2660–5.
  • 4
    Cohen H, Neumann L, Shore M, Amir M, Cassuto Y, Buskila D. Abnormal sympathovagal balance in men with fibromyalgia. J Rheumatol 2001; 28: 581–9.
  • 5
    Moldofsky H, Scarisbrick P, England R, Smythe J. Musculoskeletal symptoms and non-REM sleep disturbance in patients with “fibrositis syndrome” and healthy subjects. Psychosom Med 1975; 37: 341–51.
  • 6
    Bennett RM. Emerging concepts in the neurobiology of chronic pain: evidence of abnormal sensory processing in fibromyalgia. Mayo Clin Proc 1999; 74: 385–98.
  • 7
    Clauw DJ, Crofford LJ. Chronic widespread pain and fibromyalgia: what we know, and what we need to know. Best Pract Res Clin Rheumatol 2003; 17: 685–701.
  • 8
    Girault JA, Greengard P. The neurobiology of dopamine signaling. Arch Neurol 2004; 61: 641–4.
  • 9
    Vallone D, Picetti R, Borrelli E. Structure and function of dopamine receptors. Neurosci Biobehav Rev 2000; 24: 125–32
  • 10
    Dziedzicka- Wasylewska M, Ferrari F, Johnson RD, Mierau J, Rogoz Z, Skuza G, et al. Mechanisms of action of pramipexole: effects on receptors. Rev Contemp Pharmacother 2001; 12: 1–31.
  • 11
    Lin SC, Kaplan J, Burger CD, Fredrickson PA. Effect of pramipexole in treatment of resistant restless legs syndrome. Mayo Clin Proc 1998; 73: 497–500.
  • 12
    Yunus M, Aldag J. Restless legs syndrome and leg cramps in fibromyalgia syndrome: a controlled study. BMJ 1996; 312: 1339.
  • 13
    Holman AJ, Neiman RA, Ettlinger RE. Preliminary efficacy of the dopamine agonist, pramipexole for fibromyalgia: the first, open label, multicenter experience. J Musculoskel Pain 2004; 12: 69–74.
  • 14
    Holman AJ. Pramipexole and fibromyalgia: promise and precaution [letter]. J Rheumatol 2003; 30: 2733.
  • 15
    Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33: 160–72.
    Direct Link:
  • 16
    Burckhardt CS, Clark SR, Bennett RM. The Fibromyalgia Impact Questionnaire (FIQ): development and validation. J Rheumatol 1991; 18: 728–33.
  • 17
    Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988; 56: 893–97.
  • 18
    Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62.
  • 19
    Pincus T, Swearingen C, Wolfe F. Toward a Multidimensional Health Assessment Questionnaire (MDHAQ): assessment of advanced activities of daily living and psychological status in the patient-friendly Health Assessment Questionnaire format. Arthritis Rheum 1999; 42: 2220–30.
    Direct Link:
  • 20
    Holman AJ. Treatment of fibromyalgia with the dopamine agonist ropinirole: a 14-week double-blind pilot randomized controlled trial (RCT) with 14-week blinded extension [abstract]. Arthritis Rheum 2004; 50 Suppl 9;S698.
  • 21
    Wang GJ, Volkow ND, Logan J, Pappas NR, Wong CT, Zhu W, et al. Brain dopamine and obesity. Lancet 2001; 357: 354–7.
  • 22
    Altier N, Stewart J. The role of dopamine in the nucleus accumbens in analgesia. Life Sci 1999; 65: 2269–87.
  • 23
    Kotecha SA, Oak JN, Jackson MF, Perez Y, Orser BA, van Tol HH, et al. A D2 class dopamine receptor transactivates a receptor kinase to inhibit NMDA receptor transmission. Neuron 2002; 35: 1111–22.
  • 24
    Yunus MB. Use of a dopamine agonist in fibromyalgia: where is the evidence? J Clin Rheumatol 2003; 9: 211–4.
  • 25
    Wood PB. Fibromyalgia syndrome: a central role for the hippocampus: a theoretical construct. J Musculoskeletal Pain 2004; 12: 19–26.
  • 26
    Lopez JF, Akil H, Watson SJ. Neural circuits mediating stress. Biol Psychiatry 1999; 46: 1461–71.
  • 27
    Sapolsky RM. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 2000; 57: 925–35.
  • 28
    Petzke F, Clauw DJ. Sympathetic nervous system function in fibromyalgia. Curr Rheumatol Rep 2000; 2: 116–23.
  • 29
    Jenner P. Pharmacology of dopamine agonists in the treatment of Parkinson's disease. Neurology 2002; 58 Suppl 1:S1–8.
  • 30
    Lentz MJ, Landis CA, Rothermel J, Shaver JL. Effects of selective slow wave sleep disruption on musculoskeletal pain and fatigue in middle aged women. J Rheumatol 1999; 26: 1586–92.
  • 31
    Older SA, Battafarano DF, Danning CL, Ward JA, Grady EP, Derman S, et al. The effects of delta wave sleep interruption on pain thresholds and fibromyalgia-like symptoms in healthy subjects: correlation with insulin-like growth factor I. J Rheumatol 1998; 25: 1180–6.
  • 32
    Matinez- Lavin M, Hermosillo AG. Autonomic nervous system dysfunction may explain the multisystem features of fibromyalgia. Semin Arthritis Rheum 2000; 29: 197–9.
  • 33
    Krassioukov AV, Furlan JC, Fehlings MG. Autonomic dysreflexia in acute spinal cord injury: an under-recognized clinical entity. J Neurotrauma 2003; 20: 707–16.
  • 34
    Resta O, Rana L, Procacci V, Guido P, Picca V, Scarpelli F. Autonomic dysfunction in normotensive awake subjects with obstructive sleep apnoea syndrome. Monaldi Arch Chest Dis 1998; 53: 23–9.
View Full Article (HTML) Get PDF (113K)